Immunologic Factor
Moderna Secures Victory in EU Patent Dispute with Pfizer-BioNTech over COVID-19 Vaccine
Moderna, Pfizer, BioNTech, EU, patent dispute, COVID-19 vaccine, mRNA technology, European Patent Office (EPO), intellectual property rights, pharmaceutical industry.
WHO Approval for Takeda’s Dengue Vaccine: A Breakthrough in Global Health
WHO, Takeda, dengue vaccine, prequalification, global health, regulatory tracker, breakthrough, approval.
Pharmaceutical Giants Sanofi, Pfizer, and AstraZeneca Pump $1.87 Billion into French Operations
Sanofi, Pfizer, AstraZeneca, France, investment, pharmaceutical industry, operations, vaccine production, research and development, manufacturing.
AstraZeneca’s COVID-19 Antibody Treatment Shows Promising Results in Immunocompromised Individuals
AstraZeneca, COVID-19, antibody treatment, immunocompromised individuals, enhanced protection, clinical trials, monoclonal antibodies, virus neutralization, immune response.
AstraZeneca’s Next-Generation Covid Therapy Shines in Phase 3 Trials
AstraZeneca, Covid-19, Evusheld, Phase 3 trials, next-generation therapy, successor, antibody treatment, prevention, efficacy, safety.
Johnson & Johnson Expands into IL-13 and TSLP Market with Strategic Acquisition
Johnson & Johnson, I&I acquisition, IL-13, TSLP, competitive market, strategic expansion, pharmaceutical industry, biologics, inflammatory diseases.
FDA Rejects Hepatitis B Vaccine Update Due to Inadequate Documentation and Data
FDA, hepatitis B vaccine, vaccine update, document destruction, insufficient data, rejection
Eisai and Biogen Overcome Filing Hitch, Initiate FDA Submission for Subcutaneous Leqembi
Eisai, Biogen, FDA submission, Leqembi, subcutaneous, Alzheimer’s disease, rolling submission, BLA, clinical trials, monoclonal antibody, amyloid beta, neurodegenerative disorder
FDA Rejects Dynavax’s Heplisav-B Expansion Due to Data Gaps
FDA, Dynavax, Heplisav-B, data gaps, rejection, expansion, vaccine, hepatitis B
Novel Monthly Hemophilia A Treatment by Novos Poses Challenge to Roche’s Hemlibra
Hemophilia A, Novos, Roche, Hemlibra, monthly treatment, performance, challenge.